Tang Yan-Fen, Han Jun-Yan, Ren Ai-Min, Chen Li, Xue Tian-Jiao, Yan Yong-Hong, Wang Xi, Wang Yu, Jin Rong-Hua
Department of Respiratory, Beijing Ditan Hospital Capital Medical University, Beijing, 100015, People's Republic of China.
National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
J Inflamm Res. 2022 Aug 19;15:4751-4761. doi: 10.2147/JIR.S371283. eCollection 2022.
To explore the long-term effects of SARS-Cov-2 infection on the pulmonary function in the severe convalescent COVID-19 patients for 6 to 9 months follow-up in Beijing, China.
A total of 64 cases of COVID-19 patients were recruited for the study and discharged from the Beijing Ditan Hospital, Capital Medical University, for 6 to 9 months. COVID-19 patients were divided into non-severe (mild and moderate) and severe groups. The follow-up investigated the lung function tests, the novel coronavirus antibody (IgM and IgG), chest CT and blood tests.
About 25.00% (16/64) patients had pulmonary ventilation dysfunction and 35.9% (23/64) had diffusion dysfunction. In the severe group, 56.50% (13/23) individuals showed decreased diffusion function. The diffusion dysfunction of the severe group was significantly decreased than the non-severe group (P = 0.01). Among 56 cases, the positive rate of IgG titers was 73.2% (41/56). The result of chest CT showed 55.36% (31/56) cases in nodules, 44.64% (25/56) in strip-like changes, 37.5% (21/56) in-ground glass shadow, and 5.36% (3/56) in grid shadow, which was significantly different between the severe group and the non-severe group. Patients tended to have ground glass changes in the severe group while nodules in the non-severe group.
For the 6 to 9 months in convalescent COVID-19 patients, 56.50% (13/23) of severe patients had pulmonary diffusion dysfunction. Convalescent COVID-19 patients should have their pulmonary function regularly tested, especially those with severe illness.
探讨新型冠状病毒肺炎(COVID-19)重症康复患者6至9个月随访期间,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染对肺功能的长期影响,研究在中国北京开展。
共招募64例COVID-19患者参与本研究,这些患者均从首都医科大学附属北京地坛医院出院,出院时间为6至9个月。COVID-19患者被分为非重症(轻症和中症)组和重症组。随访调查了肺功能测试、新型冠状病毒抗体(IgM和IgG)、胸部CT及血液检测情况。
约25.00%(16/64)的患者存在肺通气功能障碍,35.9%(23/64)存在弥散功能障碍。在重症组中,56.50%(13/23)的个体弥散功能下降。重症组的弥散功能障碍明显低于非重症组(P = 0.01)。在56例患者中,IgG抗体滴度阳性率为73.2%(41/56)。胸部CT结果显示,55.36%(31/56)的病例有结节,44.64%(25/56)有条状改变,37.5%(21/56)有磨玻璃影,5.36%(3/56)有网格影,重症组和非重症组之间差异有统计学意义。重症组患者倾向于出现磨玻璃改变,而非重症组倾向于出现结节。
对于COVID-19康复患者6至9个月的随访期,56.50%(13/23)的重症患者存在肺弥散功能障碍。COVID-19康复患者应定期进行肺功能检测,尤其是重症患者。